International Journal of Hematology

, Volume 106, Issue 6, pp 842–846 | Cite as

Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood–ocular barrier

  • Mitsuhito Hirano
  • Nobuhiro Ohno
  • Ryuji Tanosaki
  • Manabu Mochizuki
  • Kyoko Ohno-Matsui
  • Kaoru Uchimaru
  • Arinobu Tojo
  • Koju Kamoi
Case Report
  • 290 Downloads

Abstract

Adult T-cell leukemia–lymphoma (ATL), a rare lymphoid malignancy with a high mortality rate, is caused by the human T-cell leukemia virus type 1. Due to its rarity and poor prognosis, ocular manifestations have yet to be well documented. The mechanisms that underlie ocular involvement in ATL patients, thus, remain poorly understood. We report the first successfully tracked case of ocular inflammation (i.e., uveitis) that developed simultaneously in conjunction with a rapid increase in ATL cells. Our findings for this case suggest that a rapid increase in ATL cells contributed to the disruption of the blood–ocular barrier, which may, thus, represent one mechanism underlying the induction of uveitis in ATL patients. Furthermore, with the development of novel therapies, the longer survival times of ATL patients have raised new issues, such as quality of vision in ATL patients. Hematologists should be aware that a rapid increase in the number of ATL cells may cause adult T-cell leukemia cell-induced uveitis.

Keywords

Adult T-cell leukemia–lymphoma Human T-cell leukemia virus type 1 Blood–ocular barrier Uveitis Ocular inflammation 

Notes

Compliance with ethical standards

Ethical approval

This study complied with all of the principles of the most recent version of the Declaration of Helsinki (updated 2008). This study was conducted in line with the guidelines of the University of Tokyo and Tokyo Medical and Dental University Ethics Committee.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Watanabe T. HTLV-1-associated diseases. Int J Hematol. 1997;66:257–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Uchimaru K, Nakamura Y, Tojo A, Watanabe T, Yamaguchi K. Factors predisposing to HTLV-1 infection in residents of the greater Tokyo area. Int J Hematol. 2008;88:565–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Uchimaru K. Current problems on the management of HTLV-1 asymptomatic carriers and ATL patients. Rinsho Ketsueki. 2011;52:1432–8.PubMedGoogle Scholar
  4. 4.
    Mahieux R, Watanabe T. Forefront studies on HTLV-1 oncogenesis. Front Microbiol. 2013;4:156.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tsukasaki K, Tobinai K. Clinical trials and treatment of ATL. Leuk Res Treat. 2012;2012:101754.Google Scholar
  6. 6.
    Liu MM, Furusato E, Cao X, Shen D, Chan CC. Ocular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1. Rare Tumors. 2010;2:e63.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kamoi K, Mochizuki M. HTLV-1 uveitis. Front Microbiol. 2012;3:270.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kamoi K, Mochizuki M. HTLV infection and the eye. Curr Opin Ophthalmol. 2012;23:557–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Sugita S, Ogawa M, Shimizu N, Morio T, Ohguro N, Nakai K, et al. Use of a comprehensive polymerase chain reaction system for diagnosis of ocular infectious diseases. Ophthalmology. 2013;120:1761–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Mochizuki M, Sugita S, Kamoi K, Takase H. A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases. Jpn J Ophthalmol. 2017;61:1–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Kitajima M, Korogi Y, Shigematsu Y, Liang L, Matsuoka M, Yamamoto T, et al. Central nervous system lesions in adult T-cell leukaemia: MRI and pathology. Neuroradiology. 2002;44:559–67.CrossRefPubMedGoogle Scholar
  12. 12.
    Kamoi K, Nagata Y, Mochizuki M, Kobayashi D, Ohno N, Uchimaru K, et al. Formation of segmental rounded nodules during infiltration of adult T-cell leukemia cells into the ocular mucous membrane. Cornea. 2016;35:137–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Mitsuhito Hirano
    • 1
  • Nobuhiro Ohno
    • 1
  • Ryuji Tanosaki
    • 3
  • Manabu Mochizuki
    • 4
  • Kyoko Ohno-Matsui
    • 4
  • Kaoru Uchimaru
    • 1
  • Arinobu Tojo
    • 1
    • 2
  • Koju Kamoi
    • 1
    • 4
  1. 1.Department of Hematology/Oncology, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  2. 2.Division of Molecular Therapy, Department of The advanced Clinical Research Center, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  3. 3.Center for Transfusion Medicine and Cell Therapy, School of MedicineKeio UniversityTokyoJapan
  4. 4.Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental ScienceTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations